VAERS reports by lot

GSK RSV lot GX3T4: VAERS reports

30 VAERS reports list lot GX3T4 as a GSK RSV vaccine, received between 2024-02-28 and 2025-05-01. Data: VAERS public files through 28 May 2026 (site extract 2026-10-28).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
30
Reports
0%
Marked serious
0
With a death outcome
9
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction1230%
General / Systemic (non-local)1025%
Musculoskeletal922%
Dermatological (non-injection-site)38%
Neurological25%
Cardiac / Cardiovascular25%
Allergic / Anaphylactic25%

Where reports came from

U.S. state of the reporter, where given (top 12).

StateReports
Texas10
Iowa3
Rhode Island2
Nevada2
New York2
Pennsylvania2
Alabama1
Arkansas1
Michigan1
Hawaii1
New Mexico1
Oklahoma1

Reports by month received

MonthReportsBar
2024-024
2024-0310
2024-044
2024-052
2024-063
2024-072
2024-093
2025-031
2025-051

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Nearby GSK RSV lots (A–Z): F59KR · G2MG3 · GE3S7 · HL594 · JP392 · KD424

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-10-28 18:08 UTC. Not medical advice. Report errors via contact.